Torrent Pharmaceuticals Limited — PPTs, 20-05-2025: Investor Presentation

1. Financial Highlights:

Torrent Pharmaceuticals posted Q4 revenues of ₹2,959 Cr, up 8% YoY, led by strong growth in India (+12%) and the US (+15%). Full-year revenue increased 7% to ₹11,516 Cr, with India driving growth at 13%. Brazil experienced a modest decline (-6% Q4, -2% FY), while Germany and other markets held steady. Profit and margin details were not provided.

2. Strategic Initiatives & Growth Drivers:

India remains the primary growth engine, showing robust double-digit expansion. The US market is gaining momentum, supported by an emphasis on complex generics and specialty products. No specific capex or technology investment details were disclosed.

3. Business Developments:

No new acquisitions or partnerships were announced, indicating a focus on organic growth across multiple markets.

4. Market Position & Competitive Advantage:

Torrent maintains a leadership position in India and is scaling in regulated markets like the US and Germany, leveraging a diversified portfolio of branded generics and formulations.

5. Investor Implications:

Consistent growth in India combined with emerging US traction suggests positive growth potential. Execution risks remain around international market dynamics and product pipeline expansion, which investors should monitor.